William Blair Analysts Lift Earnings Estimates for Biogen

Biogen Inc. (NASDAQ:BIIB) – Stock analysts at William Blair upped their Q2 2025 earnings estimates for shares of Biogen in a research report issued to clients and investors on Wednesday, February 12th. William Blair analyst M. Minter now anticipates that the biotechnology company will earn $4.20 per share for the quarter, up from their previous estimate of $3.79. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Biogen’s current full-year earnings is $16.42 per share. William Blair also issued estimates for Biogen’s Q1 2026 earnings at $3.86 EPS, Q2 2026 earnings at $4.31 EPS, FY2026 earnings at $15.20 EPS and FY2028 earnings at $18.33 EPS.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a net margin of 16.81% and a return on equity of 14.98%.

BIIB has been the subject of several other reports. Morgan Stanley decreased their price objective on shares of Biogen from $192.00 to $157.00 and set an “equal weight” rating for the company in a report on Thursday, February 13th. HC Wainwright reduced their price target on shares of Biogen from $300.00 to $241.00 and set a “buy” rating for the company in a report on Thursday, February 13th. JPMorgan Chase & Co. reduced their price target on shares of Biogen from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Monday, November 4th. Scotiabank reduced their price target on shares of Biogen from $244.00 to $224.00 and set a “sector outperform” rating for the company in a report on Thursday, February 13th. Finally, Barclays reduced their price target on shares of Biogen from $190.00 to $180.00 and set an “equal weight” rating for the company in a report on Thursday, October 31st. Seventeen research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Biogen currently has an average rating of “Hold” and a consensus target price of $211.85.

Biogen Price Performance

NASDAQ BIIB opened at $136.57 on Monday. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28. The company has a fifty day simple moving average of $146.52 and a 200 day simple moving average of $172.19. The company has a market cap of $19.90 billion, a P/E ratio of 12.34, a P/E/G ratio of 1.65 and a beta of -0.08. Biogen has a 1 year low of $128.51 and a 1 year high of $238.00.

Hedge Funds Weigh In On Biogen

Institutional investors have recently added to or reduced their stakes in the company. Lee Danner & Bass Inc. bought a new position in Biogen during the 4th quarter valued at about $25,000. Larson Financial Group LLC lifted its holdings in Biogen by 640.9% during the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 141 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in Biogen during the 3rd quarter valued at about $33,000. Colonial Trust Co SC lifted its holdings in Biogen by 9,300.0% during the 4th quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 186 shares during the last quarter. Finally, SRS Capital Advisors Inc. bought a new position in Biogen during the 4th quarter valued at about $33,000. 87.93% of the stock is owned by institutional investors.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.